Clinical trials: Allogeneic Bone Marrow Transplantation
Allogeneic Disease, Hematologic Cancer
Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT
Currently, transplantation centers across North America generally do not offer longitudinal rehabilitation programs and research is urgently needed to test the acceptability and effectiveness of these programs using innovative…
- Conditions
- Allogeneic Disease, Hematologic Cancer, Cancer Rehabilitation
- Trial name
- NCT04966156
- Testing
- CaRE-4-alloBMT plus usual care group
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- University Health Network, Toronto
Multiple Myeloma
Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma
A prospective, randomized trial of autologous bone marrow transplantation compared with allogeneic bone marrow transplantation in multiple myeloma.
- Trial name
- NCT00998270
- Testing
- Autologous bone marrow transplantation, Allogeneic bone marrow transplantation
- Where
- Iran
- Volunteers
- 185 people
- Sponsor
- Tehran University of Medical Sciences
Chronic Myeloid Leukemia
Allogeneic SCT for CML, TKI Failure After TKI Failure
The investigators will evaluate the outcomes of allogeneic stem cell transplantation which is the only curative treatment modality in the patients with chronic myeloid leukemia after failing tyrosine kinase inhibitor therapy.
- Trial name
- NCT02172365
- Where
- Canada
- Volunteers
- 350 people
- Sponsor
- University Health Network, Toronto
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.
Acute Leukemia, Chronic Myeloid Leukemia
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the…
- Conditions
- Acute Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02487069
- Testing
- HSCT from MSD, HSCT from MUD, HSCT from HRD
- Where
- China
- Volunteers
- 876 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematologic Malignancy, Bone Marrow Transplant Rejection
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor…
- Conditions
- Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT06398457
- Testing
- Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Severe Aplastic Anemia
Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia
The purpose of this study is to evaluate the effectiveness of allogeneic transplant after a reduced-intensity preparative regimen for patient, to evaluate survival, and to evaluate the side effects of this treatment.
- Trial name
- NCT01129323
- Testing
- Cyclophosphamide, Fludarabine, Rabbit ATG
- Sponsor
- City of Hope Medical Center
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
AML, MDS
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating…
- Trial name
- NCT05473910
- Testing
- SOC + TSC-101, Control, SOC + TSC-100
- Where
- 21 sites in United States
- Volunteers
- 310 people
- Sponsor
- TScan Therapeutics, Inc.
Myelodysplastic Syndrome, Acute Myeloblastic Leukemia
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients
Primary Objective: 1. To assess the self-reported symptoms and the plasma cytokine levels of AML/MDS patients pretransplantation and posttransplantation with allogeneic blood and marrow in order to identify changes in symptoms…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloblastic Leukemia, Leukemia
- Trial name
- NCT00504920
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Myelofibrosis
Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France
The investigators would like to conduct a retrospective study in five centers in France in the goal to evaluate the survival of patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis.
- Trial name
- SYMFASCT (NCT04282421)
- Volunteers
- 58 people
- Sponsor
- Central Hospital, Nancy, France
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
This study will examine the safety of clofarabine, TLI and ATG as a reduced conditioning regimen prior to allogeneic transplantation.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00697684
- Testing
- Antithymocyte Globulin, Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Beth Israel Deaconess Medical Center
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory).
- Conditions
- Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04220684
- Testing
- Cytarabine Hydrochloride, Fludarabine, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Sumithira Vasu
Family Caregivers, Bone Marrow Transplantation
Education Program to Manage Emotional Stress of Stem Cell Transplant Recipients and Their Caregivers
his study will evaluate a series of problem-solving education sessions for patients undergoing a stem cell transplant and their family caregivers.
- Trial name
- NCT00423774
- Testing
- Problem-Solving Education
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Aplastic Anemia
Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia
The purpose of this study is to reduce the regimen related toxicities and transplantation related mortality after allogeneic stem cell transplantation in adult acquired aplastic anemia (AA), the trials of reduced dose of Cy along…
- Trial name
- CyATG-FluATG (NCT01145976)
- Testing
- Cy-ATG, Flu-ATG
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Cooperative Study Group A for Hematology
Graft-versus-host Disease, Relapse
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant (BMT) for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis and treatment.
- Trial name
- NCT01941394
- Testing
- Mesenchymal stem cells
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- National Research Center for Hematology, Russia
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
This is a non-randomised, open-label phase I study of an investigational medicinal product (IMP) consisting of a HLA-A*02:01 restricted HA-1H T cell receptor transduced T cell (MDG1021) immunotherapy for relapsed or persistent…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- NCT04464889
- Testing
- MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3
- Where
- Netherlands
- Sponsor
- Medigene AG
Renal Dysfunction, Acute Renal Failure
Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol
The purpose of the study is to combine Urodilatin (ANP analogue), which will increase glomerular filtration rate (GFR), and mannitol, which will increase the rate of urinary flow and solute excretion.
- Conditions
- Renal Dysfunction, Acute Renal Failure, Mortality
- Trial name
- NCT00390624
- Testing
- URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE), MANNITOL
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rocky Mountain Cancer Centers
Leukemia, Chronic Myeloid Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell…
- Conditions
- Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Diffuse Large Cell Lymphoma
- Trial name
- AlloTreo (NCT00598624)
- Testing
- Treosulfan IV
- Where
- 12 sites in Italy
- Volunteers
- 175 people
- Sponsor
- IRCCS San Raffaele
Myelodysplastic Syndromes, Acute Leukemia
Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia
RATIONALE: Giving chemotherapy and total marrow and lymphoid irradiation before allogeneic hematopoietic cell transplant helps stop the growth of leukemia cells.
- Trial name
- NCT03408210
- Testing
- total body irradiation, total marrow and lymphoid irradiation
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences